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Abstract
The glycosylated membrane protein M of the severe acute respiratory syndrome associated
coronavirus (SARS-CoV) is the main structural component of the virion and mediates assembly and
budding of viral particles. The membrane topology of SARS-CoV M and the functional significance
of its N-glycosylation are not completely understood as is its interaction with the surface
glycoprotein S. Using biochemical and immunofluorescence analyses we found that M consists of a
short glycosylated N-terminal ectodomain, three transmembrane segments and a long,
immunogenic C-terminal endodomain. Although the N-glycosylation site of M seems to be highly
conserved between group 1 and 3 coronaviruses, studies using a recombinant SARS-CoV
expressing a glycosylation-deficient M revealed that N-glycosylation of M neither influence the
shape of the virions nor their infectivity in cell culture. Further functional analysis of truncated M
proteins showed that the N-terminal 134 amino acids comprising the three transmembrane
domains are sufficient to mediate accumulation of M in the Golgi complex and to enforce
recruitment of the viral spike protein S to the sites of virus assembly and budding in the ERGIC.
Background
Coronaviruses have a broad range of vertebrate hosts and
usually cause mild respiratory diseases in humans and
animals [1-3]. In March 2003 the world health organiza-
tion issued a global alert about a severe partially fatal res-
piratory disease named severe acute respiratory syndrome
(SARS). SARS originated in Southeast China, affected
thousands and spread to many countries worldwide via
international travel. Drastic quarantine measures and
tight travel restrictions finally contained the SARS out-
break [4,5]. In parallel, the etiologic agent of the outbreak
was identified with unprecedented speed and turned out
to be a novel coronavirus with several distinguishing fea-
tures to known coronaviruses [6-8]. The SARS outbreak
showed drastically that coronaviruses can develop into
highly pathogenic agents with the potential to threaten
public health and global economy severely [9,10].
The coronaviral membrane protein (M) is the most abun-
dant protein in the viral envelope and fulfils pivotal func-
tions in the viral life cycle. Besides mediating
incorporation of the nucleocapsid into the newly formed
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virions, M recruits all other viral structural components to
the ER-Golgi-intermediate compartment (ERGIC) where
virus assembly and budding takes place [11-13]. While
the topology of SARS-CoV M is yet unknown and in silico
analyses of its topology revealed partially contradictory
results (Fig. 1), previous publications showed that other
coronaviral M proteins consist of three transmembrane
domains with either an N-terminal ecto- and a C-terminal
endodomain (Nexo-Cendo) or an Nexo-Cexo orientation [14-
16].
SARS-CoV M is N-glycosylated at asparagine residue at
position 4 and accumulates at steady state in the Golgi
complex [17]. Whether glycosylation of M plays a role in
its intracellular distribution and assembly of viral particles
is not known. Immunofluorescence analyses demon-
strated that M is mainly retained in the ERGIC [17,18].
In the present study we have investigated the topology of
M and found that M consists of an N-terminal ectodo-
main containing the single N-glycosylation site, three
transmembrane domains and a long cytosolic C-termi-
nus. N-glycosylation is no prerequisite for accumulation
of M in perinuclear regions. By using an infectious clone
of SARS-CoV with a substitution in the N-glycosylation
site of M, we observed that N-glycosylation is dispensable
for assembly and infectivity of the virus. Furthermore, the
hydrophobic N-terminus of M containing the three trans-
membrane domains is sufficient to recruit the SARS-CoV
spike protein S to the budding compartment suggesting
protein-protein-interaction between M and S via the
transmembrane domains of M.
Results
Topology of SARS-CoV M
To predict membrane-spanning helices in SARS-CoV M,
we performed hydrophobicity analyses and secondary
structure predictions using several computer programs
(Fig. 1A). Three in four algorithms predicted three trans-
membrane helices at similar positions. However, the
tmap-program predicted only two hydrophobic domains
between amino acids 73–93 and 133–150. Further in silico
analyses also differed in the prediction of the topology of
the N- and the C-terminus of M.
To analyze the membrane topology of M experimentally,
we benefited from the fact that a fraction of recombinant
FLAG-tagged M is detectable at the plasma membrane
[17]. The FLAG epitope was fused to the N-terminus of M
and the glycosylation-deficient mutant MN4Q  and the
accessibility of the FLAG Tag at the cell surface was ana-
lyzed by immunofluorescence of native cells expressing
the two constructs. The experiments revealed that MFLAG as
well as MN4Q-FLAG were detectable at the plasma mem-
brane (Fig 1B). These results suggested that both M and
MN4Q exhibit a Nexo-orientation with the N-terminus fac-
ing the luminal or extracellular space (Fig. 1B, right
graphic).
To further characterize the membrane integration of M,
we introduced a novel glycosylation site (N-X-S) in the
predicted intraluminal loop between hydrophobic
domains 2 and 3 of the protein (Fig. 1C). To avoid a very
close proximity of the glycosylation site and the ER mem-
brane leading to sterical limitations of the oligosaccharide
transferase in the ER lumen [19], we inserted 31
hydrophilic amino acids with a central N-glycosylation
motif between amino acids 73 and 74 of M and MN4Q
(named MInsert; MN4Q Insert). The in vitro expression of MIn-
sert resulted in three protein bands (Fig. 1C, lanes 1 and 4)
which could be attributed to non-, mono- and di-glyco-
sylated forms of M by Endo H digest (Fig. 1C, lane 5).
Expression of MN4Q Insert which contains only the novel
glycosylation site between the potential transmembrane
segments 2 and 3 resulted in two M-specific bands (Fig.
1C, lanes 2 and 6). Endo H digestion revealed that the
upper band was glycosylated suggesting that the two
forms correspond to non- and monoglycosylated MN4Q
Insert. (Fig. 1C, lane 7). These results demonstrate that the
linker-domain between the putative second and third
hydrophobic domains faces the luminal site and the two
hydrophobic stretches are probably incorporated in the
lipid-layer. Therefore we hypothesize a membrane topol-
ogy of M as depicted in the right graphic in Fig. 1C.
In silico analysis using the computer program tmap identi-
fied a hydrophobic stretch between amino acids 133 and
150 suggesting an additional transmembrane domain,
which would direct the C-terminus of M into the lumen.
(Fig. 1A). To analyse, whether parts of the C-terminus of
SARS-CoV M are located in the cytoplasm, we constructed
further glycosylation mutants of M carrying single N-glyc-
osylation motifs at position 186 (MV186N) or 205 (ML205N)
(Fig. 1D). In vitro translation of these constructs in the
presence of microsomes revealed that neither MV186N nor
ML205N were glycosylated (Fig. 1D, lanes 2 and 3) suggest-
ing that the C-terminus of M is completely located in the
cytoplasm (Fig. 1D, right graphic).
In summary, we could for the first time provide experi-
mental support for a Nexo-Cendo topology of SARS-CoV M
with a luminal N-terminus, three transmembrane seg-
ments and a long cytosolic C-terminus.
Suppressed N-glycosylation of M does not impair protein 
accumulation in the Golgi complex nor the assembly and 
infectivity of a recombinant SARS-CoV
Amino acid sequence alignments demonstrated that the
N-glycosylation motif at the extreme N-terminus of M is
conserved between coronaviruses of group 1 and 3 andVirology Journal 2009, 6:79 http://www.virologyj.com/content/6/1/79
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Analysis of the membrane topology of SARS-CoV M Figure 1
Analysis of the membrane topology of SARS-CoV M. A, in silico predictions of hydrophobic domains and potential 
transmembrane segments of M using various computer algorithms. Numbers in superscript refer to the position of the first and 
the last amino acids of potential transmembrane domains (white rectangles). B, Subconfluent Huh7 cells were transfected with 
plasmids encoding M (MN-FLAG) or a glycosylation-deficient M (MN4QN-FLAG) both N-terminally fused with a FLAG-peptide. Sur-
face-staining (red fluorescence) and subsequent intracellular staining (green fluorescence) of M was performed 24 h posttrans-
fection (p.t.) using a polyclonal α-FLAG and a fluorescence-labelled secondary antibody. C, M and the glycosylation mutants 
MInsert and MN4Q Insert were in vitro translated in the presence of canine microsomal membranes and metabolically labelled with 
[35S] PROMIX (Promega). Resultant proteins were digested with Endo H. Membrane-bound proteins were pelleted and sub-
jected to SDS-PAGE analysis. Radioactive signals were visualized using Bioimager analyser (BAS-1000; Fuji). M0 – non-glyco-
sylated M; M1 – mono-glycosylated M; M2 – di-glycosylated M. D, M and the glycosylation mutants MV186N and ML205N were in 
vitro translated and analysed as described above.Virology Journal 2009, 6:79 http://www.virologyj.com/content/6/1/79
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the newly emerged SARS-CoV (Fig. 2A). To confirm these
in silico data the N-terminal N-glycosylation site of the
homologue protein of another human pathogenic coro-
navirus, HCoV-NL63, was mutated which led to the loss
of glycosylation completely as it is the case for SARS-CoV
M (data not shown) [17]. These results induced the idea
that N-glycosylation might be important for protein trans-
port, protein-protein-interactions or other steps in the
viral life cycle. Therefore, the intracellular distribution of
the glycosylation-deficient mutant MN4Q of SARS-CoV was
investigated by immunofluorescence analysis (Fig. 2B).
The staining of the ER-Golgi intermediate compartment
(ERGIC) and the recombinantly expressed MN4Q revealed
a strong colocalization suggesting that the MN4Q as well as
wild type M accumulates in the budding compartment
ERGIC and that N-glycosylation has no influence on
intracellular transport of M (Fig. 2B, right image)[17].
Recently, a T7 promoter-driven infectious cDNA-clone of
SARS-CoV was engineered [20]. To study N-glycosylation
of M in the viral context, we applied this reverse genetic
system and constructed a recombinant SARS-CoV (rec-
SARS-CoV) expressing a glycosylation-deficient M. Expres-
sion of viral proteins was confirmed by western blot
analysis using serum of a SARS-convalescent or the
human monoclonal α-M antibody S30 [17]. The serum
recognized the structural components spike- (S) and
nucleocapsid- (N) protein in cell lysates of wt and mutant
recSARS-CoV infected Vero-cells. The M specific antibody
could indeed detect the unglycosylated and the N-glyco-
sylated form of M in wt recSARS-CoV infected Vero-cells
(Fig. 3A). However, in cells infected with MN4Q recSARS-
CoV only the unglycosylated form of M was detected.
These results provide evidence that we successfully res-
cued a replication-competent recSARS-CoV expressing a
glycosylation-deficient M. To illustrate the morphology of
wt as well as mutant recSARS-CoV, we performed elec-
tronmicroscopy analysis of purified virions demonstrat-
ing that both virions share a characteristic corona-solis
like appearance (Fig. 3B, upper panel). By measuring sev-
eral virions we observed that the average size of wt and
mutant virions was the same.
To compare growth properties between wt recSARS-CoV
and mutant recSARS-CoV, we first used plaque assays. As
shown in Fig. 3B, the plaque size of the mutant virus was
similar to wt virus presuming that the spread of the virus
expressing a glycosylation-deficient M is not inhibited
(Fig. 3B, lower panel). To further analyze the growth
kinetics of both viruses, cell cultures were infected and the
viral replication efficiency was assessed by calculating the
number of viral genomes in the supernatant by real-time
RT-PCR (Fig. 3C). In FRHK4 cells (fetal rhesus monkey
kidney), wt recSARS-CoV (blue bars) as well as MN4Q rec-
SARS-CoV (red bars) exhibited a considerable 106-fold
increase in viral genomes copies within 18 h p.i. and
reached a plateau of approximately 107 viral genomes late
in infection (40 h p.i.; Fig. 3C, left panel). These results
were independent of the used cells since infection of Vero
cells with both viruses resulted in similar amounts of viral
particles late in infection (40 h p.i.; Fig. 3C, right panel).
However, infection with MN4Q recSARS-CoV resulted in a
10-fold reduction of released genome copies early in
infection compared to wt rec SARS-CoV. In general, both
recombinant viruses possessed a delayed viral replication
in infected Vero cells compared to FRHK4 cells.
In summary, we could provide evidence that a suppressed
N-glycosylation of SARS-CoV M do not have a significant
impact on protein transport and on assembly and replica-
tion of new virions in cell culture.
N-glycosylation of coronviral M Figure 2
N-glycosylation of coronviral M. A, N-terminal amino 
acid sequences of M of selected coronaviruses were aligned 
and depicted using MacVector program. B, M and the glyco-
sylation-deficient mutant MN3Q of HCoV-NL63 were in vitro 
translated and analyzed as described above. (Plasmid 
expressing HCoV-NL63 M protein was kindly provided by M. 
Müller, Bonn). C, Subconfluent Huh7 cells were transfected 
with plasmid encoding the glycosylation-deficient M (MN4QN-
FLAG) using FuGENE according to the manufacturer's proto-
col. At 24 h p.t., cells were fixed, permeabilized and incu-
bated with a polyclonal α-FLAG antibody and a rhodamine-
coupled secondary antibody. ERGIC was stained using a 
monoclonal α-ERGIC primary antibody and a FITC-coupled 
secondary antibody. The merged image is shown on the 
right.Virology Journal 2009, 6:79 http://www.virologyj.com/content/6/1/79
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Characterization of recombinant SARS-CoV expressing a glycosylation-deficient M Figure 3
Characterization of recombinant SARS-CoV expressing a glycosylation-deficient M. A, Vero cells were infected 
with wild type recombinant SARS-CoV (wt rec SARS-CoV) or the mutant MN4Q recombinant SARS-CoV (MN4Q rec SARS-
CoV) respectively with an moi of 3 pfu per cell. Cell lysates were harvested and subjected to Western blot analysis. Virus inac-
tivation was achieved by treatment with 1% SDS and boiling of the samples. Proteins were separated by SDS-PAGE and blotted 
onto PVDF membranes. To detect viral structural proteins the membrane was incubated with a serum of an immunized rabbit 
or with the human monoclonal antibody S30. B, For electron microscopic analysis, Vero cells were infected with a MOI of 1 
with wt rec SARS-CoV or MN4Q rec SARS-CoV, respectively. At 24 h p.i., viral particles were fixed, negatively stained and sub-
jected to electron microscopic analysis.Virology Journal 2009, 6:79 http://www.virologyj.com/content/6/1/79
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The hydrophilic cytosolic tail of M exhibits an 
immunogenic epitope
Previously, we could identify the M-specific antibody S30
synthesized by Epstein Barr virus-immortalized B-lym-
phocytes of a SARS convalescent [21]. To map the epitope
of this unique M-specific human monoclonal antibody,
we constructed FLAG-tagged mutants with truncations in
the C-terminal part of M. The respective mutants were
expressed in BHK-T7 cells and employed in immunoblot
and immunoprecipitation analysis (Fig. 4A and 4B). M
and M1–134 were metabolically labelled during in vitro
translation and precipitated using S30. While M was read-
ily precipitated by S30, M1–134 was not (Fig. 4B). To nar-
row down the epitope recognized by S30 in the C-
terminus of M, FLAG-tagged mutants of M were con-
structed which carried small truncations in the absolute C-
terminus (Fig. 4C and 4D). Mutants were expressed in
BHK-T7 cells and cell lysates were subjected to western
blot analysis. While all mutants were readily detected by
an anti-FLAG antibody, only mutants consisting of at least
201 amino acids could be detected by S30 (Fig. 4D, lanes
5 and 6). Unexpectedly, mutant M1–196 comprising of 196
amino acids migrated slightly slower than the mutant
consisting of 201 amino acids. Since the sequence of the
M1–196 had been verified like all other constructs, the rea-
Mapping the epitope of the human monoclonal α-M antibody S30 Figure 4
Mapping the epitope of the human monoclonal α-M antibody S30. A, An exemplary schematic representation of M 
mutants used in this study. A FLAG-epitope was fused to the C-terminus or in addition to the N-terminus. B, M1–134 was in vitro 
translated in the presence of [35S] PROMIX and subsequently immunoprecipitated using human monoclonal α-M antibody S30. 
The precipitates were subjected to SDS-PAGE and radioactive signals were visualized by autoradiography. C and D, BHK-T7 
cells were transfected with plasmids encoding various C-terminally truncated M mutants. At 24 h p.t., cells were lysed, soni-
cated and directly subjected to SDS-PAGE analysis followed by immunoblotting using polyclonal α-FLAG and human mono-
clonal α-M antibody S30 simultaneously. The proteins were visualized using an AF680-coupled α-rabbit and an IRDye800-
coupled α-human antibody and the Odyssey™ Infrared Imaging System. Mc-g, complex glycosylated form of M. Arrowheads 
indicate the specific protein bands detected by α-M S30 antibody.Virology Journal 2009, 6:79 http://www.virologyj.com/content/6/1/79
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son for the abnormal behaviour in SDS-PAGE remained
unknown.
We were not able to detect the truncated mutant M1–189.
Transient expression of MN/C1-189 possessing a FLAG-tag at
the N- and the C-terminus and subsequent Western blot
analysis revealed the expression of the mutant, which was
not detected by the S30 antibody. Taken together, it
appears that S30 recognizes a distinct linear epitope
located at the extreme C-terminus of M around amino
acid residues 196 and 201.
The hydrophobic N-terminus of M is sufficient to recruit M 
in the Golgi-complex and to retain S in perinuclear regions
M is concentrated in the Golgi compartment but the
molecular determinants for the intracellular distribution
are not understood. Therefore, we analyzed the intracellu-
lar distribution of the C-terminal truncated mutant M1–134
by immunofluorescence (Fig. 5). As expected, full-length
M accumulated in Golgi complex of transiently trans-
fected Huh7-cells (Fig. 5, upper row). The recombinant
expression of M1–134 showed strong colocalization with
Golgi-marker as well suggesting that the hydrophobic N-
terminus of M constitutes a Golgi-retention signal (Fig. 5,
lower row).
The recruitment of all coronaviral structural components
in the perinuclear region is crucial for viral assembly and
budding. However, recombinant spike protein S was
transported to the plasma membrane upon single expres-
sion (Fig. 6A, left panel), while S in SARS-CoV infected
cells was localized mainly to the perinuclear region (Fig.
6A, right panel). Thus, we explored whether M influenced
intracellular localization of S. To this end, M and S were
coexpressed and their respective intracellular localization
was analyzed by immunofluorescence (Fig. 6B, upper
row). We found that in the presence of M, S was recruited
to cellular compartments where SARS-CoV budding takes
Intracellular distribution of M and M1–134 Figure 5
Intracellular distribution of M and M1–134. Huh7 cells were transfected with plasmids encoding M or M1–134 as described in 
Fig. 2. At 24 h p.t., cells were fixed, permeabilized and incubated with a polyclonal α-FLAG and a monoclonal α-Giantin anti-
body followed by a FITC-coupled α-rabbit and a rhodamine-coupled α-mouse antibody. The merged images are shown on the 
right hand side, respective proteins are given on the left hand side.Virology Journal 2009, 6:79 http://www.virologyj.com/content/6/1/79
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Coexpression of M and S Figure 6
Coexpression of M and S. A, Huh7 cells were transfected with plasmid as described in Fig. 2. At 24 h p.t., cells were fixed, 
permeabilized and viral proteins were stained with a rabbit polyclonal α-S serum and a rhodamine-coupled α-rabbit secondary 
antibody. SARS-CoV (strain Frankfurt) infected Vero cells were fixed, permeabilized and incubated with the same antibodies as 
described above. B, Huh7 cells coexpressing MC or the truncated form M1–134 together with S were fixed, permeabilized and 
incubated with a rabbit α-S serum and a mouse monoclonal α-FLAG antibody followed by a FITC-coupled α-mouse and a 
rhodamine-coupled α-rabbit secondary antibody. The merged images are shown on the right hand side and respective, coex-
pressed proteins are given on the left hand side of the panels.Virology Journal 2009, 6:79 http://www.virologyj.com/content/6/1/79
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place. Replacing M by the mutant containing only the
hydrophobic N-terminal part of the protein, M1–134, we
observed that S is still found in the perinuclear region and
plasma membrane transport is prevented (Fig. 6B, lower
row). In summary this experiment showed that coexpres-
sion with at least the first 134 amino acids of M induced a
redistribution of the surface protein S to the perinuclear
region which is consistent with the idea that M recruited S
to site of assembly and budding of SARS-CoV.
Discussion
M proteins of coronaviruses with low pathogenic poten-
tial for humans are quite well understood in terms of syn-
thesis, transport and function. M protein of the highly
pathogenic SARS-CoV shows little amino acid sequence
homology to other coronaviruses which makes predic-
tions difficult [22]. In this report, we analyzed SARS-CoV
M with respect to membrane topology, N-glycosylation
and functional interaction with the surface protein S.
Membrane topology and functional analysis of M
As shown previously, SARS-CoV M acquires one oligosac-
charide side chain at asparagine residue 4 suggesting a
luminal orientation of the N-terminus [17]. This result
was supported and extended in the present manuscript by
immunofluorescence analyses demonstrating that even
the glycosylation-deficient M exhibits an N-terminal ecto-
domain. The topology of the hydrophobic stretches in M
was determined using artificially incorporated N-glyco-
sylation sites postulating the presence of three transmem-
brane domains and a long cytosolic C-terminus. The
topology is different to other coronaviruses e.g. the trans-
missible gastroenteritis virus (TGEV) M [15]. The pre-
sented membrane topology model of SARS-CoV M
presumes a "Nexo-Cendo"-orientation (Fig. 7).
We further identified an immunogenic B-cell epitope at
the very C-terminus of M. These results supported the
observation that the cytosolic tail and in particular the
amino acids between position 195 and 210 of M can serve
as an efficient immunogen in antibody production (He et
al., 2005; Imgenex 5125A). Obviously, M contains several
immunogenic epitopes since sera from SARS patients rec-
ognized additional epitopes located in the C- and N-ter-
minal region of M as well [23,24]. Our attempts to
generate antibodies to peptides representing the absolute
N-terminus of M, however, were unsuccessful (not
shown).
Presented functional analyses showed that the first 134
amino acids of SARS-CoV M comprising the three trans-
membrane domains are crucial for accumulation of M in
the Golgi-complex. Similar findings have been reported
for infectious bronchitis virus (IBV), which suggested
retention signals in the first transmembrane domain of M
[25]. An additional retention signal located in the
cytosolic tail is postulated for MHV M [26]. Whereas M of
MHV and IBV seem to be retained completely in perinu-
clear regions [11], M of TGEV, of the feline coronavirus
(FCoV) and of SARS-CoV are also exposed at the plasma
membrane [17,27,28].
N-glycosylation of SARS-CoV M
Detailed analyses revealed that accumulation of M
beyond the budding compartment in the Golgi-complex
is a common feature of all investigated coronaviruses
[11,17,29-31]. In this study we observed that N-glycosyla-
tion had no impact on the intracellular distribution of
recombinant SARS-CoV M. By utilizing a novel reverse
genetic system of SARS-CoV we also did not observe any
significant influence of N-glycosylation of M in terms of
viability, assembly and budding efficiency and infectivity
of recombinant SARS-CoV in cell culture [20]. Supportive
for these results are data by de Haan et al., showing that
O-glycosylation of murine hepatitis virus (MHV) M is dis-
pensable for assembly and spread of the virus [32,33].
Most likely the conserved glycosylation of M serves other
functions. Previous studies on TGEV revealed an influence
of glycosylation of M on interferon induction [34]. In the
same direction point experiments in which an artificially
introduced N-glycosylation in MHV M caused a strong
interferon-α and -β induction while glycosylation-defi-
cient MHV M is a poor interferon-α inducer [32].
Influence of M on the intracellular distribution of S
Surface spikes composed of the SARS-CoV glycoprotein S
confer the name-giving shape of coronaviral particles in
electron microscopy analysis [35]. The spikes coat the
viral envelope and facilitate interaction of the virus with
the cellular receptor and subsequent fusion with the
plasma membrane [36-40]. Hence, incorporation of S
into the viral envelope is essential for infectivity of
released progeny virions [41-43]. A retention signal
located at the cytosolic C-terminus of most coronaviral S
proteins prevents surface expression of S [44,45]. How-
ever, we and others could observe that upon single expres-
sion, S of SARS-CoV is detectable at the plasma membrane
Membrane topology model of SARS-CoV M protein Figure 7
Membrane topology model of SARS-CoV M protein.Virology Journal 2009, 6:79 http://www.virologyj.com/content/6/1/79
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[36,45,46]. Thus, the question arose whether interaction
with other viral proteins supported retention of S. Previ-
ous studies on MHV showed an interaction between M
and S and emphasized the impact of this interaction on
viral morphogenesis [12,42,43,47]. Here, we observed
that M suppressed the surface transport of S and may thus
functionally support the ER retrieval signal identified by
McBride and Machamer [46]. Essential for the retrieval of
S was the N-terminus of M.
Conclusion
In summary, by using N-glycosylation mutants and subse-
quent Endo H digest we could establish a membrane
topology model of SARS-CoV M with three transmem-
brane domains and a Nexo-Cendo-orientation. N-glycosyla-
tion of M is neither essential for transport and topology of
M nor for its function in replication of recombinant SARS-
CoV. Further in vivo studies using the generated N-glyco-
sylation-deficient SARS-CoV are necessary to elucidate the
role of conserved N-glycosylation during immune
response of the infected host. Finally, our data revealed
that the N-terminal part of M induces the retrieval of S to
the ERGIC.
Materials and methods
Cells and Viruses
BSR T7/5 cells (BHK-21 cell clone), which constitutively
expressed T7 RNA polymerase, were cultured as described
by Bucholz et al. [48]. Monolayer cultures of the human
hepatoma cell line Huh7 and the African green monkey
kidney cell line Vero were grown at 37°C and 5% CO2 in
Dulbecco's modified Eagles Medium (DMEM, Gibco)
supplemented with 10% fetal calf serum (FCS) 100 U/ml
penicillin, and 0.1 mg/ml streptomycin. For the infection
of Vero cells SARS-CoV (Frankfurt strain; accession no.
AY310120) was used at a multiplicity of infection of
approximately 0.1.
Molecular Cloning of M and Glycosylation-Mutants of M
For expression of M and the glycosylation-deficient M
N4Q, the respective genes were cloned under the control
of the T7 RNA polymerase promoter into the pTM1 plas-
mid as described previously (Voss et al., 2006). Cloning of
the glycosylation mutants MV186N and ML205N was per-
formed using QuickChange site-directed mutagenesis kit
(Stratagene) to substitute valine and leucine by asparagine
at the indicated amino acid positions. The construction of
pTM1-MInsert and pTM1-MN4QInsert was performed by con-
secutive PCR-steps and subsequent cloning into pTM1
vector. First, fragments encoding amino acids 1–73 and
74–221 of M were amplified using pTM1-M or pTM1-
MN4Q as template and the following primers: M1–73 (5'-
CGGAATTCATGGCAGACAACGGTACTATTACCG-3' and
5'-acggtagcggttgtatgcgtaattaattctgtagacaacagc-3') and M74–
221(5'-gacgatgacaagccaaaagagtgggtgactggcgggattgcg-3' and
5'-CGAGGATCCTTACTGTACTAGCAA AGCAATATTG-
3'). In addition, a fragment encoding a stretch of 31
hydrophilic amino acids with a central N-glycosylation
site was amplified using the partially complementary oli-
gonucleotides 5'-
TACGCATACAACCGCTACCGTATTGGAAACTATAAATTA
AATACAACTATTAAGGACCTGGACTACAAGGAC-3' and
5'-
CTCTTTTGGCTTGTCATCGTCGTCCTTGTAGTCCAGGTC
CTTAATAGTTGTATTTAATTTATAGTTTCC-3'. The three
resulting PCR fragments were fused by recombinant PCR
leading to MInsert or MN4Q Insert respectively and cloned into
the EcoRI and BamHI restriction sites of pTM1 vector. All
constructs were verified by restriction analysis and
sequencing.
Molecular Cloning of M Truncation Mutants
DNA fragments encoding the C-terminally truncated M
mutants were generated by PCR with pTM1-M as template
and the following primers: M1–107 (5'- CCGGAATTCATGG
ACTACAAGGACGACGATGACAAGGCAGACAACGGTAC
TATTACCGTTG-3' and 5'-CGAGGATCCTTATGAGCGGG-
TACGAGC-3'); M1–134 (5'-CGGAATTCATGGCAGACAA
CGGTACTATTACCG-3' and 5'-CGAGGATCCTTACTTGT
CATCGTCGTCCTTGTAGTCTTCCATGAGCGGTCTGGT-
CAC-3'); M1–159  (5'-CGGAATTCATGGCAGACAACGG-
TACTATTACCG-3' and 5'-CGAGGATCCTTACTTGTCAT
CGTCGTCCTTGTAGTCGTCACAGCGCCCTAGGGAGTG-
3'); M1–189 (5'-CGGAATTCATGGCAGACAACGGTACTAT-
TACCG-3' and 5'-CGAGGATCCTTACTTGTCATCGTCG
TCCTTGTAGTCATCAGTGCCTACACGCTGCGAC-3');
MN/C1-189 (5'-CCGGAATTCATGGACTACAAGGACG
ACGATGACAAGGCAGACAACGGTACTATTACCGTTG-3'
and 5'-CGAGGATCCTTACTTGTCATCGTCGTCCTTG-
TAGTCATCAGTGCCTACACGCTGCGAC-3'); M1–196  (5'-
CGGAATTCATGGCAGACAACGGTACTATTACCG-3' and
5'-
CGAGGATCCTTACTTGTCATCGTCGTCCTTGTAGTAGTT
GTATGCAGCAAAACCTGAATCAGTGCC-3'); M1–201  (5'-
CGGAATTCATGGCAGACAACGGTACTATTACCG-3' and
5'-
CGAGGATCCTTACTTGTCATCGTCGTCCTTGTAGTCTC-
CAATACGGTAGCGGTTGTATGCAGC-3'); M1–207  (5'-
CGGAATTCATGGCAGACAACGGTACTATTACCG-3' and
5'-
CGAGGATCCTTACTTGTCATCGTCGTCCTTGTAGTCTGT
ATTTAATTTATAGTTTCCAATACGGTAGCGG-3'); M1–212
(5'-CGGAATTCATGGCAGACAACGGTACTATTACCG-3'
and 5'-
CGAGGATCCTTACTTGTCATCGTCGTCCTTGTAGTCGC
TACCGGCGTGGTCTGTATTTAATTTATAG-3'). The frag-
ments were cloned into the EcoRI and BamHI cleavage
sites of pTM1. The integrities of all constructs were verified
by restriction analysis and sequencing.Virology Journal 2009, 6:79 http://www.virologyj.com/content/6/1/79
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Indirect Immunofluorescence Analysis
To perform surface staining of transiently transfected
Huh7 cells, cells were grown on glass cover slides and
transfected with the plasmids indicated in figure legends
as described previously (Voss et al., 2006). At 24 h pt, cells
were put on ice and successively incubated with a polyclo-
nal α-FLAG (Sigma) and a secondary rhodamine-coupled
α-rabbit antibody (Dianova), respectively. Intracellular
staining was achieved by subsequent fixation with 4%
PFA/DMEM for 15 min at room temperature, permeabili-
zation with 0.1% Triton X-100 in PBS for 10 min and
additional incubation for 1 h with a polyclonal α-FLAG
and a FITC-coupled secondary α-rabbit antibody (Dian-
ova) at room temperature. To characterize the influence of
M on the intracellular transport of S, subconfluent Huh7
cells were co-transfected with pTM1-MC-FLAG or pTM1-M1–
134 and pcDNA.3.1-S (kindly provided by M. Eickmann,
Marburg) using FuGENE (Roche) according to the manu-
factor's protocol. In addition, a plasmid was cotransfected
encoding the T7 DNA-dependent RNA-polymerase sup-
porting the expression of the M mutants. At 24 h p.t., the
cells were fixed with 4% PFA/DMEM for 15 min and per-
meabilized for 10 min with 0.1% Triton X-100. Then,
unspecific binding sites were blocked using 3% BSA/PBS
before the protein of interest was stained using rabbit pol-
yclonal α-FLAG (Sigma) and/or a human monoclonal α-
S antibody [21], respectively. The secondary antibodies
used were donkey α-rabbit FITC-coupled and α-human
rhodamine-coupled antibody (Dianova). All steps were
performed at room temperature. Fluorescence images
were taken with fluorescence microscope (Zeiss Axiovert
200M).
Infectious cDNA-clone of SARS-CoV
Engineering of a T7-driven cDNA clone of SARS-CoV has
been published previously [20]. Briefly, the viral genome
of SARS-CoV (Frankfurt 1 isolate) was subdivided into
seven fragments by RT-PCR and subsequently cloned into
pCR2.1 (Invitrogen) or pSMART vectors (Lucigen) using
appropriate restriction enzymes. In order to achieve a full
length SARS-CoV cDNA clone the present constructs were
subjected to further restriction/ligation steps into pBelo
vectors finally assembling a pBelo-SARS clone under the
control of the T7 promoter. The full-length BAC-con-
structs were linearized, in vitro transcribed and electropo-
rated in BHK-21 cells using GenePulser (Biorad). Harvest
and purification of infectious virus was done under BSL4-
conditions. According to this approach, we constructed a
cDNA-subclone with a substitution in the N-glycosylation
site of M by site-directed mutagenesis (Quick change,
Stratagene) using wild type pSMART-F as template. Subse-
quent cloning steps and the rescue of a recombinant
SARS-CoV expressing glycosylation-deficient M was per-
formed as described above for wild type recombinant
SARS-CoV.
Growth kinetics of recombinant viruses using real time RT-
PCR
Vero or FRHK4 cells were infected with plaque-purified wt
recSARS-CoV or MN4Q recSARS-CoV with a MOI of 0.05,
respectively. At the indicated time points, viral RNA was
isolated using QIAamp viral RNA kit according to the
manufactor's protocol and subjected to real-time RT-PCR.
To monitor viral replication, the viral polymerase gene
was amplified using RT PCR [6]. Fluorescence signals were
read by LightCycler® (Roche).
Electronmicroscopy Analysis
Negative staining of purified viral particles was carried out
as described elsewhere [22,49].
Amino acid sequence alignments
In silico protein analysis were performed with the follow-
ing programs: TMpred, PRODIV, HMMTOP, and tmap.
Other Methods
in vitro translation and subsequent Endo H-digest or
immunoprecipitation analyses as well as transient trans-
fection of BHK-T7 cells and Western blot analyses were
carried out as described previously [17].
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